INSM Stock Cash Flow Statements

Insmed Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Insmed Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31

operating activities
net income	-321,686,000	-256,583,000	-235,548,000	-220,524,000	-300,609,000	-157,091,000	-186,061,000	-158,933,000	-244,809,000	-159,764,000	-160,123,000	-131,145,000	-95,645,000	-94,621,000	-112,978,000	-112,714,000	-117,321,000	-91,641,000	-102,213,000	-63,659,000	-61,854,000	-66,364,000	-52,988,000	-60,682,000	-66,514,000	-74,153,000	-91,573,000	-87,743,000	-76,437,000	-68,524,000	-65,384,000	-45,179,000	-44,672,000	-37,414,000	-37,760,000	-36,579,000	-33,532,000	-30,962,000	-28,607,000	-27,369,000	-23,990,000	-23,224,000	-14,298,000	-17,327,000	-8,854,000	-13,678,000	-15,451,000	-9,382,000	-9,696,000	-6,845,000	-8,162,000	-34,590,000	-10,018,000	-6,894,000	-5,844,000	-330,000	-378,000	118,000	2,306,000	-150,000	-1,601,000	117,795,000	-3,964,000	-2,163,000	-4,667,000	-4,873,000	-3,297,000	-3,912,000	-2,500,000	-10,253,000	-21,428,000	-12,372,000	-8,912,000	-13,427,000	-12,885,000	-13,756,000	-8,524,000	-5,764,000	-5,837,000	-7,596,000	-9,011,000	-4,759,000	-2,451,000	-2,398,000	-3,240,000	-2,209,000	-18,497,000			-6,107,000
adjustments to reconcile net income to net cash from operating activities:
depreciation	2,484,000	1,883,000	1,478,000	1,459,000	1,436,000	1,588,000	1,475,000	1,493,000	1,311,000	1,248,000	2,183,000	851,000	958,000	1,286,000	2,119,000	2,238,000	2,385,000	2,388,000	2,318,000	2,295,000	2,268,000	2,266,000	1,939,000	1,004,000	1,176,000	1,069,000	925,000	954,000	929,000	769,000		714,000	738,000	716,000	674,000	568,000	514,000	463,000	447,000	432,000																																							3,000	7,000	10,000	14,000	15,000	23,000	28,000	30,000	22,000	92,000	114,000	118,000
amortization of intangible assets	1,263,000	1,263,000	1,263,000	1,263,000	1,263,000	1,263,000	1,263,000	1,263,000	1,263,000	1,263,000	1,264,000	1,263,000	1,263,000	1,263,000	1,262,000	1,264,000	1,263,000	1,263,000	1,258,000	1,248,000	1,248,000	1,249,000	1,248,000	1,249,000	1,248,000	1,248,000
stock-based compensation expense	42,976,000	39,262,000	26,554,000	25,545,000	23,286,000	21,450,000	19,983,000	19,993,000	18,359,000	16,443,000	14,950,000	15,654,000	14,259,000	12,823,000	11,520,000	12,231,000	11,735,000	10,535,000	8,779,000	8,909,000	9,468,000	9,002,000	5,888,000	6,794,000	7,353,000	6,936,000	6,035,000	7,902,000	6,629,000	5,674,000	4,741,000	4,741,000
amortization of debt issuance costs	1,676,000	1,822,000	1,748,000	1,485,000	1,800,000	1,851,000	1,752,000	1,840,000	2,004,000	1,724,000						541,000	457,000	350,000	349,000	350,000	349,000	349,000	350,000	349,000	349,000	349,000	350,000	415,000	286,000	299,000	27,000
paid-in-kind interest capitalized			0	6,662,000	6,329,000	6,242,000	6,170,000	6,001,000	5,745,000	5,456,000
royalty financing non-cash interest expense	5,192,000	5,023,000	5,065,000	5,264,000	4,893,000	4,822,000	4,830,000	10,170,000	1,231,000	2,615,000
accretion of discount on marketable securities	-7,578,000	-8,332,000	-11,027,000	-6,170,000	0	-1,963,000	-3,092,000
finance lease amortization expense	678,000	678,000	678,000	678,000	678,000	678,000	678,000	678,000	678,000	678,000	114,000	481,000	636,000	729,000	269,000	270,000	269,000	270,000	269,000	89,000	360,000	360,000
non-cash operating lease expense	888,000	686,000	1,358,000	619,000	-4,905,000	6,516,000	783,000	1,124,000	4,808,000	2,491,000
change in fair value of deferred and contingent consideration liabilities	59,000,000	18,300,000	-14,800,000	14,682,000	103,700,000	-11,900,000	15,700,000	8,997,000	13,500,000	-9,500,000	-1,800,000	5,238,000	-12,622,000	-11,618,000	-966,000
change in fair value of interest rate swap			-870,000	3,852,000	-384,000	-2,362,000	-1,970,000	1,301,000	-1,184,000	1,533,000
changes in operating assets and liabilities:
accounts receivable	-6,142,000	5,361,000	-11,817,000	-35,000	-4,035,000	2,955,000	-4,535,000	-5,137,000	-1,431,000	-860,000	-983,000	1,344,000	-4,986,000	-1,798,000	-5,243,000	-1,020,000	-789,000	-1,066,000	-1,366,000	-23,000	1,981,000	2,078,000	-3,886,000	-3,708,000	-2,291,000	-3,832,000																					0	0	0	757,000	-317,000	-137,000	-134,000	302,000	-48,000	12,000	-1,000	56,000	74,000	-108,000	-97,000	8,000	-50,000	-22,000	277,000	-77,000	-225,000	-25,000	111,000	130,000	9,000	-145,000
inventory	-4,976,000	-1,021,000	-2,122,000	-6,569,000	-7,755,000	-598,000	-4,434,000	-1,098,000	-6,894,000	-1,187,000	-2,338,000	-100,000	-1,516,000	2,240,000	1,132,000	-7,031,000	-8,803,000	-2,754,000	-6,064,000	-7,956,000	-4,828,000	-2,332,000	-5,000,000	-3,153,000	-7,478,000	-5,650,000																																									0	0	0	576,000		-24,000
prepaid expenses and other current assets	-6,534,000	-16,941,000	2,799,000	842,000	1,507,000	-19,330,000	3,461,000	-1,041,000	3,044,000	-3,199,000	722,000	-2,295,000	6,853,000	-2,752,000	-3,452,000	5,387,000	-9,540,000	2,056,000	-3,745,000	-4,793,000	1,083,000	4,341,000	1,438,000	-5,568,000	-3,527,000	-1,061,000
other assets	2,347,000	10,168,000	2,710,000	-10,074,000	15,366,000	333,000	-3,169,000	-9,447,000	-2,227,000	-5,231,000	-12,220,000	2,508,000	-9,242,000	-6,289,000	-3,441,000	1,629,000	-2,892,000	-19,731,000	-1,475,000	-1,535,000	-1,683,000	-1,568,000	-703,000	-3,218,000	-5,043,000	-7,044,000																																		-91,000	-115,000	44,000	44,000	75,000	-83,000	134,000	-5,000	-28,000	-176,000	52,000	52,000	51,000	-157,000	50,000	49,000	58,000	-90,000	74,000	306,000	706,000	-802,000	-159,000	120,000	121,000	-339,000	488,000				103,000
accounts payable and accrued liabilities	25,658,000	-61,490,000	41,130,000	725,000	35,082,000	-32,345,000	21,709,000	-6,778,000	9,065,000	-8,841,000	34,874,000
other liabilities	-815,000	-2,167,000	-4,578,000	-620,000	-604,000	-6,144,000	-5,362,000	-468,000	-3,736,000	-1,422,000	8,768,000																																																																							154,000	9,000	-31,000	-10,000	-121,000				-297,000
net cash from operating activities	-205,569,000	-262,088,000	-195,979,000	-180,916,000	-122,952,000	-184,035,000	-130,819,000	-136,333,000	-122,792,000	-146,303,000	-103,149,000	-89,828,000	-102,301,000	-105,161,000	-84,132,000	-75,445,000	-75,444,000	-128,281,000	-66,792,000	-58,668,000	-35,953,000	-57,935,000	-44,404,000	-52,368,000	-80,030,000	-73,847,000	-69,538,000	-65,488,000	-54,912,000	-68,039,000	-48,221,000																-8,926,000	-9,188,000	-7,286,000	-5,612,000	-6,065,000	-8,008,000	-11,023,000	-5,109,000	-8,917,000	-1,040,000	2,004,000	231,000	775,000	-1,139,000	-8,554,000	-2,094,000	-2,880,000	-3,119,000	-2,097,000	-3,896,000	-3,212,000	-3,346,000	-6,824,000	-11,873,000	-10,803,000	-11,886,000	-7,837,000	-11,678,000	-6,209,000	-7,867,000	-7,394,000	-6,295,000	-6,452,000	-6,544,000	-7,286,000	-4,619,000	-2,683,000	-2,781,000	-3,066,000	-2,232,000	-3,859,000			-8,903,000
capex	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0																0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			0
free cash flows	-205,569,000	-262,088,000	-195,979,000	-180,916,000	-122,952,000	-184,035,000	-130,819,000	-136,333,000	-122,792,000	-146,303,000	-103,149,000	-89,828,000	-102,301,000	-105,161,000	-84,132,000	-75,445,000	-75,444,000	-128,281,000	-66,792,000	-58,668,000	-35,953,000	-57,935,000	-44,404,000	-52,368,000	-80,030,000	-73,847,000	-69,538,000	-65,488,000	-54,912,000	-68,039,000	-48,221,000																-8,926,000	-9,188,000	-7,286,000	-5,612,000	-6,065,000	-8,008,000	-11,023,000	-5,109,000	-8,917,000	-1,040,000	2,004,000	231,000	775,000	-1,139,000	-8,554,000	-2,094,000	-2,880,000	-3,119,000	-2,097,000	-3,896,000	-3,212,000	-3,346,000	-6,824,000	-11,873,000	-10,803,000	-11,886,000	-7,837,000	-11,678,000	-6,209,000	-7,867,000	-7,394,000	-6,295,000	-6,452,000	-6,544,000	-7,286,000	-4,619,000	-2,683,000	-2,781,000	-3,066,000	-2,232,000	-3,859,000			-8,903,000
investing activities
purchase of fixed assets	-3,484,000	-10,070,000	-6,772,000	-3,689,000	-6,783,000	-4,679,000	-2,153,000	-2,854,000	-4,883,000	-3,398,000	-4,691,000	-582,000	-2,904,000	-1,701,000	-1,142,000	-1,481,000	-3,485,000	-1,181,000	-933,000	-747,000	-1,881,000	-2,679,000	-13,038,000	-14,592,000	-10,610,000	-4,028,000	-3,027,000	-1,851,000	-2,847,000	-5,365,000	-1,700,000																-168,000	-27,000	-29,000	-66,000	-424,000	-487,000	-54,000	-14,000
purchase of marketable securities	-276,681,000	-630,518,000	-577,470,000				-296,044,000	1,000			0	0	0	-99,706,000
maturities of marketable securities	508,000,000	721,000,000	716,000,000	0	0	300,000,000	300,000,000	10,000,000	20,000,000	45,000,000	25,000,000
net cash from investing activities	227,835,000	80,412,000	131,758,000	-1,003,471,000	-6,783,000	295,321,000	1,803,000	7,147,000	-274,156,000	41,602,000	20,309,000	49,418,000	-2,904,000	-101,407,000	-51,218,000	-8,401,000	-3,485,000	-1,181,000	-1,515,000	-747,000	-1,881,000	-2,679,000	-13,038,000	-14,592,000	-10,610,000	-4,028,000	-4,751,000	-1,851,000	-2,847,000	-5,365,000	-1,700,000																44,589,000	-28,000	4,120,000	12,841,000	10,482,000	8,640,000	-1,249,000	16,487,000	9,976,000	-589,000	-10,053,000	6,624,000	-14,392,000	-6,873,000	-87,750,000	127,755,000	3,245,000	4,571,000	-744,000	5,601,000	9,066,000	0	0	-500,000	-517,000	-1,487,000
financing activities
proceeds from exercise of stock options and espp	36,965,000	29,704,000	13,740,000	26,880,000	68,571,000	4,052,000	7,636,000	2,341,000	7,283,000	1,139,000															10,455,000	3,049,000
proceeds from issuance of common stock			-12,000	370,978,000			114,461,000	0			258,770,000				0	0			1,000	-47,000			0	-104,000							-47,000							0									-1,000				0	0							0	0															4,368,000	88,000	78,000	87,000	8,165,000	4,000			20,000	12,962,000	-42,000	11,000	17,000	0	135,000	18,000
payments of principal of 0.75% convertible senior notes due 2028
payments of finance lease principal	-732,000	-706,000	-686,000	-658,000	-645,000	-621,000	1,166,000	-1,092,000	-971,000	-320,000		-336,000	-135,000	-359,000		-269,000	-264,000	-258,000		-179,000	-298,000	-292,000
net cash from financing activities	857,806,000	28,998,000	159,305,000	397,200,000	781,493,000	3,022,000	123,263,000	1,249,000	44,326,000	-399,000	743,387,000	37,116,000	6,311,000	6,459,000	5,710,000	2,536,000	597,597,000	6,703,000	12,011,000	6,102,000	250,756,000	2,134,000	9,238,000	1,358,000	271,633,000	3,049,000	1,797,000	605,000	5,549,000	378,792,000	433,000	378,222,000	1,869,000	565,000	9,692,000	47,000	81,000	825,000	225,643,000	1,475,000	108,438,000	-60,000	337,000	67,790,000	596,000	22,000	10,130,000	25,630,000	9,698,000	-34,000	-18,000	-22,000	11,000	-21,000	-3,000	0	1,000	-231,000	-229,000	-233,000	3,847,000	-518,000	-494,000	-557,000	-486,000	-553,000	778,000	0	17,047,000	297,000	443,000	6,000	2,000	52,050,000	4,368,000	88,000	78,000	32,844,000	8,165,000				20,000	12,962,000	-42,000	11,000	17,000	0	135,000	18,000
effect of exchange rates on cash and cash equivalents	1,005,000	895,000	-1,505,000	1,839,000	-688,000	-953,000	1,014,000	2,168,000	-3,403,000	-29,000	-1,144,000	1,849,000	-732,000	-969,000	-134,000	-461,000	-92,000	-246,000	299,000	155,000	47,000	-7,000	1,000	-26,000	36,000	-15,000	-10,000	-21,000	-42,000	28,000	-25,000	77,000	39,000	12,000			31,000
net increase in cash and cash equivalents	881,077,000	-151,783,000			651,070,000	113,355,000					659,403,000	-1,445,000			-129,774,000	-81,771,000			-55,997,000	-53,158,000			-48,203,000	-65,628,000	181,029,000	-74,841,000	-72,502,000	-66,755,000	-52,252,000	305,416,000	-49,513,000							-24,058,000
cash and cash equivalents at beginning of period	0	555,030,000	0	0	0	482,374,000	0	0	0	1,074,036,000	0	0	0	716,782,000	0	0	0	532,756,000	0	0	0	487,429,000	0	0	0	495,072,000	0	0	0	381,165,000	0	0	0	162,591,000	0	0	282,876,000	0	0	159,226,000	0	0	113,894,000	0	0	90,782,000	0	0	0	14,848,000	0	0	0	10,743,000	0	0	0	12,740,000	-252,000	0	0	2,397,000	0	0	0	3,554,000		0	0	24,112,000		0	0	18,835,000	0	0	0	9,222,000	0	0	0	29,526,000	0	0	0	27,337,000		0	0	51,250,000
cash and cash equivalents at end of period	881,077,000	403,247,000	93,579,000	-785,348,000	651,070,000	595,729,000	-4,739,000	-125,769,000	-356,025,000	968,907,000	659,403,000	-1,445,000	-99,626,000	515,704,000	-129,774,000	-81,771,000	518,576,000	409,751,000	-55,997,000	-53,158,000	212,969,000	428,942,000	-48,203,000	-65,628,000	181,029,000	420,231,000	-72,502,000	-66,755,000	-52,252,000	686,581,000	-49,513,000	339,614,000	-34,775,000	125,839,000	-22,591,000	-29,763,000	252,872,000	-24,058,000	200,473,000	134,554,000	84,614,000	-18,554,000	101,251,000	53,437,000	-4,846,000	79,434,000	45,793,000	16,414,000	6,532,000	22,043,000	4,399,000	610,000	-12,261,000	22,100,000	1,056,000	-1,629,000	-8,048,000	19,364,000	-14,098,000	-8,245,000	-92,457,000	127,540,000	-129,000	895,000	-3,327,000	4,706,000		-3,346,000	10,223,000	12,036,000		-13,367,000	-10,851,000	59,207,000	-1,841,000	-7,779,000	-7,316,000	35,771,000	1,713,000	-6,546,000	-10,852,000	24,907,000	-2,663,000	10,181,000	-3,108,000	25,116,000		-5,086,000	-6,100,000	42,365,000
supplemental disclosures of cash flow information:
cash paid for interest	13,269,000	13,122,000	15,240,000	8,632,000	8,485,000	8,210,000	8,326,000	7,970,000	7,902,000	11,589,000	2,715,000	2,438,000	2,629,000	2,375,000	2,688,000	2,291,000	1,640,000	4,271,000	339,000	4,028,000	438,000	4,381,000	3,000	3,939,000	2,000	3,939,000	1,314,000	3,699,000	1,000	1,275,000	1,289,000	1,302,000	1,301,000	1,273,000	899,000	597,000	975,000	724,000	843,000	663,000	473,000	467,000	463,000	472,000	468,000	476,000	234,000	161,000	1,000	2,000	1,000	2,000						3,000	72,000	-52,000	24,000	38,000	52,000	53,000	61,000	68,000	68,000	70,000	70,000	71,000	71,000	83,000	82,000	83,000	281,000
cash paid for income taxes	677,000	2,176,000	248,000	689,000	354,000	1,208,000	75,000	518,000	358,000	1,004,000	91,000	432,000	559,000	635,000	107,000	454,000	325,000	672,000	34,000	308,000	58,000	414,000	19,000	120,000	22,000	178,000		34,000	39,000	54,000		21,000	24,000	17,000
payments of equity issuance costs						-409,000
vertuis acquisition							0	0	0	10,250,000
adrestia acquisition							0	0
cash acquired in asset acquisition							0	0
proceeds from issuance of term loans
proceeds from issuance royalty financing agreement
payment of debt issuance costs							0	0	0	-1,218,000					-16,000	311,000											-2,000	0	-94,000	-14,141,000
net decrease in cash and cash equivalents								-125,769,000	-356,025,000	-105,129,000				-201,078,000				-123,005,000				-58,487,000
loss on extinguishment of debt															0	0											4,418,000	0	0	-2,209,000
accretion of debt discount																8,318,000	7,482,000	4,907,000		4,776,000						4,406,000	4,348,000	4,289,000	4,231,000	3,021,000
cash paid for business acquisition															216,000
payment on extinguishment of 1.75% convertible senior notes due 2025															0	0
payment of principal of 1.75% convertible senior notes due 2025
proceeds from issuance of 0.75% convertible senior notes due 2028															0	0
proceeds from issuance of term loan
noncash operating lease expense											536,000	1,675,000	7,396,000	2,369,000	1,371,000	1,668,000	4,342,000	5,208,000	764,000	-604,000	4,236,000	1,536,000
pari milestone upon regulatory approvals
other financing activities
amortization of debt issuance costs and accretion of debt discount												822,000	821,000	822,000
cash from business acquisition
proceeds from exercise of stock options, espp, and rsu vestings												4,069,000	6,446,000	6,818,000
payment of principal on 1.75% convertible senior notes due 2025																0
accounts payable													-16,921,000	13,363,000	11,279,000	-7,696,000	9,115,000	-20,273,000	20,705,000	-3,055,000	8,006,000	4,169,000	-6,376,000	2,694,000	-10,783,000	9,499,000	1,334,000	555,000	2,809,000	-828,000	4,525,000	-1,688,000			-861,000	695,000	527,000				-1,096,000	-247,000	3,889,000		-319,000	1,124,000	4,075,000	-213,000	319,000	545,000	830,000	-417,000	-1,161,000	1,632,000	-2,869,000	-481,000	479,000	121,000	-269,000	-130,000	-1,956,000	1,390,000	160,000	29,000	284,000	-100,000	172,000	53,000	-3,571,000	-2,936,000	3,403,000	900,000	641,000	1,275,000	-1,026,000	63,000	390,000	-1,080,000	-1,359,000	373,000	1,833,000	1,114,000	22,000	-904,000	397,000	204,000	-1,765,000			-1,186,000
accrued liabilities, accrued compensation and other													6,445,000	-22,978,000
proceeds from exercise of stock options, espp, and rsu vesting																	6,566,000	6,961,000	12,177,000	6,328,000	5,142,000	2,426,000	4,735,000
accrued liabilities and other
accrued compensation																3,760,000	5,780,000	-15,107,000	8,849,000	3,051,000	4,072,000	-10,191,000	5,186,000	3,736,000	-6,053,000	-5,937,000																					626,000	732,000	339,000	-285,000
accrued expenses and other																	3,384,000	-4,686,000	-62,000	2,239,000	-5,372,000	-7,480,000	-6,210,000	3,609,000	7,067,000	323,000	9,320,000	8,802,000	8,077,000	-6,283,000	8,716,000				800,000
accretion of debt discount and back-end fee on debt																						4,650,000
proceeds from issuance of 1.75% convertible senior notes due 2025																											0	0	0	450,000,000
payment of debt principal and extinguishment costs
payment of financing lease principal
proceeds from tenant improvement allowance
pari milestone upon fda approval
payment on extinguishment of debt
payment of debt																											0	0	0	-55,000,000
accretion of debt discount and back-end fee																								4,526,000
accretion of back-end fee on debt																											0	0	0	50,000
prepaid expenses and other assets																											-1,199,000	-662,000	-1,436,000	-2,217,000	-1,731,000	-1,180,000	-224,000	352,000													-5,000	88,000	-526,000	263,000	138,000	12,000
proceeds from issuance of debt
cash paid for taxes																																																0	2,000	2,000		0				136,000
proceeds from exercise of stock options																												605,000	5,643,000	142,000	480,000	519,000	1,869,000	565,000	0	47,000	81,000	825,000	2,701,000	1,475,000	438,000	56,000	353,000	794,000	626,000	51,000
depreciation and amortization																																									355,000	175,000	167,000	171,000	156,000	148,000	149,000	138,000	138,000	136,000	110,000	79,000	79,000	75,000	29,000	0	0	25,000	46,000	60,000	396,000	205,000	230,000	251,000	270,000	292,000	147,000	91,000	86,000	82,000	472,000	88,000	83,000	2,726,000	5,656,000	5,668,000	1,347,000	226,000
accrual of the end of term charge on the debt																																						19,000	11,000	27,000	24,000	29,000	33,000	29,000	48,000	49,000
cash paid (received) for income taxes
amortization of debt discount and debt issuance costs																																	30,000	31,000	175,000	37,000	38,000	114,000	123,000	106,000	91,000	90,000	102,000	20,000	118,000	118,000
accretion of backend fee on debt
stock based compensation expense																																		4,032,000	5,045,000	4,615,000	4,219,000	3,796,000	3,439,000	4,522,000	3,256,000	2,978,000	2,358,000	1,457,000	3,999,000	954,000	1,463,000	505,000	518,000	495,000	508,000	439,000	485,000	167,000	151,000	86,000	64,000	65,000	117,000	503,000	483,000	1,439,000	345,000	207,000	165,000	133,000	294,000	98,000	73,000	56,000	204,000	200,000	211,000	270,000
accrual of backend fee on debt																																		171,000
net (decrease) / increase in cash and cash equivalents
cash paid / (received) for income taxes																																			23,000
cash received for taxes																																						0	0	994,000	0	0	4,389,000
accrued expenses and other current liabilities																																						-321,000	160,000	1,723,000
payments on capital lease obligations																																															-29,000	-29,000	-28,000	-34,000	-18,000	-22,000	-21,000	-21,000
decrease in cash and cash equivalents																																																				610,000																													-10,852,000	-4,619,000			-3,108,000	-2,221,000
gain on sale of asset																																															0	0	0	-5,000									294,000	0	-13,000	-127,755,000
accrued expenses and deferred rent																																												2,459,000	-338,000	1,787,000	891,000
accrued lease expenses																																															-66,000	-64,000	-65,000	-64,000
purchases of fixed assets
proceeds from sale of asset																																												0	0	2,000	0	0
maturity of certificate of deposit
net cash (used in) / provided by investing activities
net proceeds from issuances of common stock
increase in cash and cash equivalents																																															45,793,000	16,414,000	6,532,000	7,195,000				11,357,000	1,056,000	-1,629,000	-8,048,000	6,624,000	-13,846,000	-8,245,000	-92,457,000	125,143,000			-3,327,000	1,152,000	6,632,000	-3,346,000	10,223,000	-12,076,000	-10,877,000	-13,367,000	-10,851,000	40,372,000	-1,841,000	-7,779,000	-7,316,000	26,549,000	1,713,000				-2,663,000							-8,885,000
supplemental disclosures of non-cash investing and financing activities:
value of warrant exercised by converting the warrant into shares of common stock																																												0
gain on sale of assets
accrued lease expense
maturity of a certifcate of deposit
sales of short-term investments																																															64,414,000	-1,000	4,144,000	12,907,000	10,482,000	9,249,000	181,000	16,588,000	24,414,000	21,500,000	42,846,000	26,393,000
borrowings of long-term debt, net of issuance costs
net proceeds from issuance of common stock
unrealized gain on investments																																																199,000	-30,000	216,000	-421,000	-246,000	303,000	-179,000
value of warrant granted in connection with debt financing
gain on sale of short-term investments
impairment loss																																																			0
income tax receivable																																																							59,000	-59,000
deferred revenue																																																			-421,000	226,000	-49,000	-158,000	304,000	-340,000	-39,000	79,000
cash consideration for merger, net of cash acquired
purchases of short-term investments																																																			424,000	-122,000	-1,376,000	-87,000	-7,705,000	-22,089,000	-52,899,000	-19,769,000	-14,098,000
repayment of convertible notes																																																							0	0	0	-231,000	-230,000	-231,000	-232,000	-553,000	-553,000	-552,000	-553,000	-553,000
other																																																							3,000	0			3,000	8,000	6,000	25,000	59,000	-5,000			55,000	0			184,000	6,000	107,000	28,000
capital lease obligations incurred
unrealized (gain) loss on investments
accretion of beneficial conversion charge
fair value of warrant granted in connection with debt financing
conversion of series b preferred stock into common stock
issuance of common stock upon merger
issuance of preferred stock upon merger
amortization of financing costs
proceeds from issuance of debt, net of issuance and financing costs
supplemental disclosures of cash flow information
supplemental disclosures of non-cash investing and financing activities
fair value of warrants in connection with debt																																																0
accrued expenses																																																	1,687,000	-609,000	371,000	390,000	247,000	-341,000
proceeds from issuance of debt net of issuance and financing costs
restricted stock unit liability																																																											0	0	0	-113,000
asset retirement obligation																																																											0	0	0	-2,217,000					148,000	148,000	148,000	147,000	148,000	148,000	148,000	148,000	147,000				189,000	117,000
interest payable																																																							0	0	0	-1,000	-1,000	-1,000	-7,000	-3,000	-2,000	-3,000	-2,000	-3,000					-4,000	-1,000	0	-24,000	-54,000	-209,000	235,000	80,000
cash received from asset sale																																																											-294,000	0	13,000	127,755,000
warrants converted into shares																																																											-2,000	0											259,000	0	0	8,810,000
cash paid (received) for taxes
purchase of capital leases
adjustments to reconcile net income to net cash
provided by operating activities:
accretion of beneficial conversion feature																																																				0	0	-9,175,000
see accompanying notes to unaudited consolidated financial statements
adjustments to reconcile net
prepaid expenses																																																						108,000	127,000	-23,000	-259,000	77,000
used in provided by operating activities:
change in trading securities
realized loss on investments																																																															0			392,000
accrued project costs & other																																																										46,000	-74,000	554,000	-125,000	-141,000
payroll liabilities																																																							300,000	95,000	161,000	-355,000	159,000	-614,000	-4,013,000	4,595,000	-180,000	-545,000	379,000	168,000	-653,000	41,000	-871,000	812,000	-850,000	462,000	764,000	-648,000	210,000	330,000	-373,000	224,000	234,000	411,000
income tax liability																																																												-625,000	-1,544,000	2,794,000
deferred rent																																																											29,000	0	0	-65,000
certificate of deposits																																																													0	10,000
supplemental information
used in operating activities:
stock options issued for services																																																																0			-1,000	0	31,000	8,000	20,000	19,000	20,000	20,000	20,000
change in certificate of deposits																																																											0
decreases in short-term investments
deferred income																																																												-39,000	38,000	-70,000	111,000	-634,000	554,000	26,000
(increases) decreases in short-term investments
stock and stock options issued for services
impairment of property, plant & equipment
purchases of investments																																																																			0	0	0	-500,000
purchases of property, plant and equipment
public offering																																																																			0	0
issuance costs																																																																			0	0			0	0	-105,000	-316,000
total proceeds from issuance of common stock																																																															59,000	-5,000			55,000	0			443,000	6,000	2,000	51,762,000
accrued project costs																																																																-356,000	520,000	12,000		188,000	-155,000	-547,000			1,350,000	-1,986,000	1,795,000	-103,000	-461,000	-125,000	117,000	-517,000	444,000	-907,000
decreases of short-term investments																																																																4,571,000	-744,000	5,601,000
loss on investments
costs incurred in conjunction with issuance of debt																																																																											0	0	0	-2,428,000
cash restricted to restricted letters of credit																																																																						297,000	0	0			0	0	0	185,000
non-cash stock acceleration																																																																											0	1,000
impairment of property, plant and equipment
decreases (increases) of short-term investments
proceeds from issuance of convertible debt with detachable stock warrants																																																																											0			35,000,000
changes in cash restricted to restricted letters of credit																																																																			723,000	0
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
public offering - issuance of 23 million shares																																																																							0	0	0	43,240,000
inventories
accrued project costs and other																																																																							889,000												-353,000			-739,000				-1,396,000
restructuring reserve																																																																								-84,000	-83,000	-82,000	-121,000	-80,000	-80,000	-78,000	-105,000	-78,000	-76,000	-76,000	-45,000	-84,000	-85,000	-84,000
purchases of property, plant & equipment
purchase of property, plant and equipment
decrease in cash restricted to restricted letters of credit																																																																										288,000
net income per share																																																																										-130		-100	-60	-130				-120
pro-forma fair value stock compensation expense																																																																										-560,000		426,000	-57,000	-560,000				-480,000
pro-forma net income																																																																										-6,324,000		-4,806,000	-2,817,000	-6,324,000				-5,239,000
pro-forma net income per share																																																																										-140		-90	-60	-140				-140
due from taisho pharmaceutical co., ltd.																																																																																			0	0	0	199,000	1,534,000	533,000	1,393,000	-138,000
furniture and office equipment
accumulated depreciation
property and equipment
stock based employee compensation cost
asset retirement obligations																																																																													148,000	148,000
proceeds from issuance of convertible debt
stock issued for services																																																																															0					0
cash restricted to support letters of credit
cash in restricted letters of credit																																																																																-6,000
amortization of goodwill
goodwill impairment charge
operational restructuring—non-cash
recognition of deferred revenues																																																																																							0
(gain) loss on sale of marketable securities
issuance of stock for services
changes in operating assets and liabilities
proceeds from marketable securities matured and sold
purchases of property and equipment
operational restructuring																																																																																							-586,000
initial license fee — taisho
non-cash stock compensation
purchased research and development
other current assets
purchases of marketable securities
acquisition of celtrix pharmaceuticals, inc., net of cash acquired
repayment of notes receivable from stock sales
decrease (increase) in cash and cash equivalents																																																																																							-3,842,000
see accompanying notes.
gain on sale of marketable securities

We provide you with 20 years of cash flow statements for Insmed stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Insmed stock. Explore the full financial landscape of Insmed stock with our expertly curated income statements.

The information provided in this report about Insmed stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.